We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AnaSpec Introduces a Suite of Phospho-Specific Anti-Her2 Antibodies
Product News

AnaSpec Introduces a Suite of Phospho-Specific Anti-Her2 Antibodies

AnaSpec Introduces a Suite of Phospho-Specific Anti-Her2 Antibodies
Product News

AnaSpec Introduces a Suite of Phospho-Specific Anti-Her2 Antibodies


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "AnaSpec Introduces a Suite of Phospho-Specific Anti-Her2 Antibodies "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

With experience in the synthesis of phospho-specific peptides, AnaSpec has introduced a full suite of phospho-specific ErbB-2 (Her-2) polyclonal antibodies. These phosphorylated antibodies show no cross reactivity and are specific for phospho-tyrosine at position 877, 1112, 1222 and 1248.

The HER-2/neu, also known as c-erbB2, or CD340 proto-oncogene encodes a 185-kDa transmembrane receptor protein. It has partial homology with the epidermal growth factor receptor and shares intrinsic tyrosine kinase activity with that receptor. HER2 plays a role in oncogenesis in breast, ovarian, gastric, and lung carcinoma and endocrine tumors.

HER2 is constitutively activated in the absence of ligand and signaling occurs through phosphorylation of specific tyrosine residues which serve as docking sites for the adaptor molecules SHC and GRB2 with subsequent activation of Ras-ERK and PI-3K pathways. HER2 activation of the extracellular signal-regulated kinase (ERK) pathway is primarily dependent on phosphorylation of Y1248/1253 of HER2 and mutation of this residue substantially diminishes the transforming potential of HER2. Other important phosphorylation sites of HER-2 include Y877 and Y1112.

AnaSpec offers several anti-Her-2/neu (c-erbB2) antibodies developed against the phosphorylated tyrosine-containing Her-2/neu sequences, and corresponding antibodies raised to the same sequence but surrounding non-phosphorylated tyrosine.

Listing of Her-2 Antibodies:

Anti - ErbB-2 (Her-2)

Anti - ErbB-2 (Her-2) (pTyr877) 

Anti - ErbB-2 (Her-2) (paired 877) 

Anti - ErbB-2 (Her-2) (pTyr1112) 

Anti - ErbB-2 (Her-2) (paired 1112) 

Anti - ErbB-2 (Her-2) (pTyr1222)

Anti - ErbB-2 (Her-2) (paired1222)

Anti - ErbB-2 (Her-2) (pY1248)

Anti - ErbB-2 (Her-2) (paired1248).

Advertisement